SCHEMBL7716340

SCHEMBL7716340

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCOCC(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.71
PPARG P37231 5/20 0.62
ALDH1A1 P00352 5/20 0.62
PPARD Q03181 4/20 0.62
PPARA Q07869 4/20 0.62
F7 P08709 4/20 0.62
F3 P13726 4/20 0.62
FFAR1 O14842 3/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
KDM4E B2RXH2 2/20 0.62
LMNA P02545 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP19A1 P11511 2/20 0.62
FABP4 P15090 2/20 0.62
HPGD P15428 2/20 0.62
ALOX15 P16050 2/20 0.62
NR4A2 P43354 2/20 0.62
HSD17B10 Q99714 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
PTGS1 P23219 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6928120 1.00 EPHX2 (0.71) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL6923085 0.98 EPHX2 (0.69) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL6293226 0.98 EPHX2 (0.69) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL6293227 0.98 EPHX2 (0.69) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL1602954 0.93 EPHX2 (0.62) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL1602949 0.93 EPHX2 (0.62) EPHX2PPARGALDH1A1PPARDPPARA
SCHEMBL1627678 0.90 EPHX2 (0.71) EPHX2PPARGPPARDPPARAF7
SCHEMBL1627821 0.90 EPHX2 (0.71) EPHX2PPARGPPARDPPARAF7
SCHEMBL1627823 0.90 EPHX2 (0.71) EPHX2PPARGPPARDPPARAF7
SCHEMBL20830249 0.90 PTGS1 (0.66) EPHX2PPARGALDH1A1PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US disclosed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US disclosed
US-6376688-B1 Modified polyunsaturated fatty acids PEPTIDE TECHNOLOGY LIMITED (AU) 2002-04-23 US disclosed
EP-0869941-B1 MODIFIED POLYUNSATURATED FATTY ACIDS PEPTECH LTD (AU) 2001-12-12 EP disclosed
EP-0869941-A1 MODIFIED POLYUNSATURATED FATTY ACIDS PEPTIDE TECHNOLOGY LTD (AU) 1998-10-14 EP disclosed
EP-0869941-A4 1998-10-14 EP disclosed
WO-1996011908-A1 MODIFIED POLYUNSATURATED FATTY ACIDS PEPTIDE TECHNOLOGY LIMITED (AU) 1996-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB EPHX2 1239/4885PPARG 239/4885ALDH1A1 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.